Acadia calls early halt to Nuplazid psychosis trial after promising interim results

Acadia calls early halt to Nuplazid psychosis trial after promising interim results

Source: 
Fierce Pharma
snippet: 

Acadia was stung hard after its schizophrenia hopes for flagship Nuplazid fell flat back in late July. On the heels of that failure, Acadia is calling off a trial in dementia-related psychosis (DRP) after it saw promising interim results for the drug.